Primary Patency Success of Arteriovenous Shunts in Hemodialysis Patients: A 28-Month Prospective Study

Background Arteriovenous (AV) shunts are vital for providing long-term vascular access in hemodialysis patients. While brachiocephalic and radiocephalic shunts are commonly employed, data on their primary patency rates and associated complications in resource-limited settings such as Yemen remain scarce. This study aimed to evaluate the primary patency success of AV shunts and identify factors influencing their outcomes in hemodialysis patients at Al-Thawra Modern General Hospital. Methods This prospective observational study was conducted over 28 months, from April 2021 to August 2023, at Al-Thawra Modern General Hospital in Sana'a, Yemen. A total of 163 patients with chronic renal failure requiring AV shunt creation for hemodialysis were included. Data on patient demographics, comorbidities, shunt characteristics, and postoperative outcomes were collected. Primary patency was assessed at the 8-month follow-up interval. Statistical analysis was performed to identify factors associated with shunt patency. Results Among the enrolled 163 patients, the median age was 43.12 years, with 61.3% undergoing brachiocephalic shunt creation. The overall primary patency rate at 8 months was 87.7%, with brachiocephalic shunts exhibiting a significantly greater patency rate (93.0%) than radiocephalic shunts (67.3%) (p = 0.02). Complications occurred in 25% of patients, with pseudoaneurysm formation being the most common complication (6.1%). Factors such as shunt type, patient age, and comorbidities (e.g., diabetes) significantly influence patency outcomes. Conclusion Compared with radiocephalic shunts, brachiocephalic shunts demonstrated superior primary patency rates, suggesting that they may be a preferable option for long-term hemodialysis access in the studied population. These findings emphasize the need for individualized patient management and careful postoperative monitoring, particularly in resource-limited settings such as Yemen, to optimize AV shunt outcomes.